Cardiometabolic syndrome (CMS) is a constellation of metabolic dysfunction characterized by insulin resistance and impaired glucose tolerance, atherogenic dyslipidemia, hypertension and intra-abdominal adiposity (IAA). Other names used for cardiometabolic syndrome are insulin resistance syndrome, syndrome X, Reavans syndrome, Beer belly syndrome, etc.
The components of this syndrome individually and interdependently are strong risk factors for high cardiovascular morbidity and mortality. People with cardiometabolic syndrome are two times more likely to die from coronary heart disease and three times more likely to have heart attack and stroke. IAA is a major contributor to increased cardiometabolic risk.
CMS involves a group of interrelated abnormalities (obesity, dyslipidemia, hyperglycemia, and hypertension) that increase the risk for cardiovascular disease and type 2 diabetes. This is a common metabolic disorder that increases in prevalence as the population becomes more obese. CMS was introduced as a diagnostic category to identify individuals who may respond to lifestyle changes as well as drug treatment when needed, with the goal of decreasing the risk of cardiovascular disease and type 2 diabetes mellitus.
Cardiology research Journals like Clinical Cardiology and Cardiovascular Medicine (CCCM) provides a global open access platform to put forth the ongoing research, reviews articles related to all heart related disease, its treatment, case reports and many more.